I.v. BU has been proven to have better bioavailability, reliable systemic drug exposure with more predictable blood levels and lower toxicity than oral BU when used as part of conditioning regimens before hematopoietic SCT (HSCT). Some studies have shown that once-daily i.v. BU had the same clinical efficacy as i.v. BU administered four times daily. To observe the clinical efficacy and pharmacokinetics (PK) of once-daily i.v. BU and to evaluate the influence of glutathione S-transferase (GST) gene polymorphisms on once-daily i.v. BU PK in adult Chinese patients with allogeneic HSCT, we analyzed 25 patients receiving related or unrelated donor transplant conditioned with i.v. BU-based regimens. With a median follow-up of 32.7 months, the 2-year OS and EFS were 64 and 63.8% for all the patients, respectively, and the 2-year cumulative incidence of relapse for all patients was 18.3%. On the basis of HPLC analysis, the mean clearance and mean daily area under the curve (AUC) of i.v. BU were calculated as 4.02 mL/min per kg and 3380.77 μM/min, respectively. The estimated C max was 1.031 ± 0.0325 μg/mL. The estimated t 1/2 and V d values were 3.618 ± 0.1932 h and 1.212 ± 0.0352 L/kg. The once-daily i.v. BU-based conditioning regimen was very well tolerated with minor toxicity in patients, most likely because of dose assurance with predictable PK. There was no GSTA1 *B/*B homozygous patient in our Chinese patients. A significant association between BU metabolism and GSTA1 polymorphism was observed. The GSTA1 *A/*B genotype group showed a significantly higher AUC (P o0.0001), higher C max (P = 0.0003) and lower clearance (P = 0.0007) than the GSTA1
INTRODUCTION
Allogeneic hematopoietic SCT (allo-HSCT) is an established curative treatment for patients with various malignant and nonmalignant diseases. The BU/CY chemotherapy regimen is one of the most commonly used non-TBI-based conditioning treatments with acceptable safety and efficacy. I.v. BU has been proven to have better bioavailability, reliable systemic drug exposure with more predictable blood levels and lower toxicity than oral BU. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] I.v. formulation of BU has become the preferred option in conditioning treatment for HSCT. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] However, most experiences with i.v. BU were the traditional four times daily dosing. 3, 7, 9, 11, 12 In recent years, studies have shown that once-daily i.v. BU had the same clinical efficacy as i.v. BU administered four times daily; the pharmacokinetic profiles and post-transplant complications were also similar for once-daily i.v. BU and traditional four times daily i.v. BU. 4, 8, 10, [13] [14] [15] [16] [17] [18] Nevertheless, the clinical outcomes and the study of pharmacokinetics (PK) of once-daily i.v. BU in Asian adult populations are still scanty.
It is reported that BU is metabolized mainly in the liver by glutathione S-transferases (GSTs), a family of phase II detoxification enzymes that catalyze the conjugation of glutathione to various xenobiotics. [19] [20] [21] [22] [23] GSTA1 is the predominant GST isoenzyme involved; GSTM1 and GSTP1 have 46 and 18% of the activity of GSTA1 in BU metabolism, respectively. 23 Although some studies on pediatric patients showed a significant correlation between GST polymorphic genotype and the clearance of i.v. BU, the researches on adult Asian patients with once-daily i.v. BU are still less. [24] [25] [26] The metabolism of certain chemotherapeutic drugs in different races may vary owing to the polymorphism of the specific enzymes. Therefore, we conducted this study to observe the clinical efficacy and PK of once-daily i.v. BU as part of a conditioning therapy for allo-HSCT and to evaluate the influence of GST gene polymorphisms on BU PK in adult Chinese patients.
of blood and collection of clinical data in accordance with the Declaration of Helsinki. The characteristics of the patients are summarized in Table 1 . The median age was 31 years (range 13-61 years). The primary diseases included ALL (n = 8), AML (n = 10), CML (n = 4) and high-risk myelodysplastic syndrome (MDS, n = 3). A total of five patients were either Hepatitis B (HBV) carriers or had chronic HBV. All patients were EBV-VCA (Epstein Barr virus-viral capsid antigen, IgG) positive, CMV-DNA negative, CMV-IgM negative and CMV-IgG positive. All donors had high-resolution molecular typing for HLA-A, -B, -C, HLA-DRB1 and DQB1.
Conditioning, GVHD prophylaxis and supportive care
Once-daily i.v. BUCY conditioning regimen was used in relatives of HLA full-matched donors. Cytarabine (Ara-C) was administered at a dose of 2-4 g/m 2 per day on days − 10 and − 9. I.v. BU was used at a dose of 3.2 mg/ kg per day on days − 8, − 7 and − 6. The daily dose was diluted to 10 times the original solution volume and was administered using an infusion pump for 6 h. CY was applied at a dose of 1.8 g/m 2 per day on days − 5 and − 4. Patients with a HLA-mismatched related donor or a MUD also received anti-lymphocyte globulin (Porcine ALG, 20 mg/kg daily from days − 4 to − 1).
For GVHD prophylaxis, standard protocol was followed, with CsA plus MTX administration. CsA was given i.v. at a dose of 2.5 mg/kg per day every 12 h since day − 10. After gastrointestinal symptoms were improved, CsA was taken orally at a dose of 5 mg/kg per day. The plasma concentration of CsA was monitored weekly so that it could be maintained at the range of 0.166-0.332 μmol/L. MTX was used at a dose of 15 mg/m 2 on day 1 and 10 mg/m 2 on days +3, +6 and +11. Mycophenolate mofetil, in combination with CsA and MTX, was used in relatives of HLA-mismatched transplantation, unrelated donor transplantation and transplantation with reduced-intensity conditioning. Mycophenolate mofetil was orally administered from the beginning of conditioning therapy at a dose of 1.0 g/day. It could be maintained at a reduced dose of 0.5 g/day after transplantation or gradually reduced according to individual conditions. Once patients developed grade 2 or more than grade 2 acute GVHD, Methylprednisolone at a dose of 1-2 mg/kg per day and/or CD25 MoAb at a dose of 1 mg/kg per day were added.
Patients received phenytoin (400 mg/day) for seizure prophylaxis. Mesna was given to prevent hemorrhagic cystitis (HC). For HVOD prophylaxis, lipo-prostaglandin E1(20 μg/day, − 7d to +30 days) was used. Patients routinely received G-CSF at a dose of 5 μg/kg per day from day +5 to neutrophil engraftment. Transfusion was given to keep platelet level 420 × 10 9 /L and Hb 470 g/L. Regular screenings of CMV-DNA in plasma were performed weekly until 180 days post transplant or withdrawal of immunosuppressant.
Engraftment
For all patients, engraftment was defined as the first of the three successive days with an ANC ⩾ 0.5 × 10 9 /L. Primary engraftment failure was considered as the failure to reach an ANC of 0.5 × 10 9 /L by day +30. Secondary graft failure was initial engraftment with documented donorderived hematopoiesis followed by loss of graft function without recurrent malignancy. Platelet engraftment was defined by the first of the seven consecutive days with a count ⩾ 20 × 10 9 /L without transfusion support. The engraftment was documented with DNA chimerism from blood using short tandem repeat-PCR. Conventional cytogenetic analysis with G-banding or FISH was used to analyze the Y-chromosome in sexmismatched cases.
Toxicity evaluation
Toxicities observed after transplantation were graded according to Common Terminology Criteria v4.0. and classified between grades I and IV. HC was defined as macroscopic hematuria accompanied by pain on voiding. Hepatotoxicity was determined according to liver function tests performed before transplantation and twice weekly post transplantation. VOD was diagnosed according to previously described criteria. 27 Pharmacokinetic analysis Blood samples were obtained from patients at time points of 2, 4, 6, 8, 12, 16 and 22 h after the start of the infusion of BU. After plasma was separated, the samples were stored at − 70°C until analysis. The BU peak concentrations (C max ) and the corresponding peak time (T max ) were measured with HPLC (API 3200 LC/MS/MS System with Analyst 1.5 workstation). 4 The area under the plasma concentration versus time curve (AUC) per BU dose was calculated by dividing the administered drug dose by the final plasma clearance estimate, and the plasma clearance was determined by modeling all plasma concentrations versus time data for each patient. Parameters such as volume of distribution of the central compartment, elimination rate constant and microconstants were estimated, and steady-state volume of distribution (V d ), half-lives (t 1/2 ) and clearance were calculated from the primary parameters. 5 The PK modeling was performed using an one-compartment model. 28 The pharmacokinetic parameters were calculated by Drug and Statistics Software (DAS ver3.0.4) program and compared by statistical analysis.
DNA extraction and GST analysis
Pretransplant genomic DNA was isolated from peripheral blood lymphocytes and extracted using a Qiagen DNA extraction kit (Qiagen (Suzhou) Translational Medicine Co., Ltd., Suzhou Industrial Park, China). The GSTA1 haplotype was determined by investigating the four sequence variants of the human GSTA1 proximal promoter that define the *A and *B alleles (−631 T or G, − 567 T, − 69C, − 52 G, designated as hGSTA1*A; and − 631G, − 567G, − 69 T, − 52 A, designated as hGSTA1*B). 29 In addition, the GSTP1 haplotype was determined by genetic variant for GSTP1(313 A/G). The promoter region of the GSTA1 gene was amplified with the forward primer GSTA1-F (5′-GGATCTAGGGATTTCTATATGG-3′) and the reverse primers GSTA1-R (5′-ACCGTCCTGGCTCGACAA-3′). The promoter region of the GSTP1 gene was amplified with the forward primer GSTP1-F (5′-CTGAGACCCACTGAGGTTAC-3′) and the reverse primers GSTP1-R (5′-GTTACTTGGCTGGTTGATGT-3′). The PCR conditions were as follows: initial denaturation at 95°C for 5 min, 40 cycles of denaturation at 96°C for Abbreviations: ATG = anti-human thymocyte globulin; MDS = myelodysplastic syndrome; MMF = mycophenolate mofetil; MUD = matched unrelated donor.
Influence of GST gene polymorphisms on BU PK J Yin et al 30 s, annealing at 55°C for 1 min and extension at 72°C for 1 min, followed by a final extension at 72°C for 5 min. The single-nucleotide polymorphisms in the GSTA1 and GSTP1 genes were separately genotyped by pyrosequencing.
Statistical analysis
OS and EFS were estimated from the date of transplantation using Kaplan-Meier curves. Significances were expressed as log rank. Cumulative incidence of non-relapse mortality (NRM) was calculated and compared with Gray's method. 30 Differences in baseline characteristics were compared with Wilcoxon rank-sum test for numerical or ordinal variables, and χ 2 -test or Fisher's exact test for categorical variables and Student's t-test for continuous variables. Po0.05 is regarded as significant and indicated in bold font.
RESULTS

Engraftment
One patient died of cerebral hemorrhage on day +10 before engraftment. All the remaining patients achieved engraftment (median time of 12 days, range 9-16 days) for neutrophils and a median of 16 days (range 9-64) for platelets. All patients had documented full donor chimerism.
Infection and treatment-related toxicity All patients received the once-daily i.v. BU regimen as prescribed, and in no case was the treatment discontinued or interrupted because of severe adverse effects. No grade IV regimen-related toxicity was recorded, and no seizure, no central nervous system or pulmonary toxicity were observed among these patients; three patients experienced grade I-II oral/esophageal mucositis, which is well tolerated in the absence of analgesic. A total of 11 patients had grade I or grade II gastrointestinal reactions including nausea, vomiting, abdominal pain and diarrhea; all these discomforts were relieved by symptomatic treatment. Although six patients developed HC 30 days post transplantation, it was considered to have no correlation with regimen-related toxicity; rather, in these lateonset HC, BK virus infection was detected in three out of six patients. Apart from transient reversible increases in bilirubin and serum alanine aminotransferase caused by the use of CsA for GVHD prophylaxis, no other signs of serious liver toxicity were recorded and no HVOD was diagnosed. GVHD GVHD was graded and staged according to the standard criteria. 31 In this study, acute GVHD was documented in 16 patients (64.0%), of whom seven had grade III-IV disease (28.0%). Chronic GVHD was observed in 17 patients (68.0%) and nine of them were extensive (36.0%).
GST polymorphism In all, 72% (18) of the patients were of GSTA1 *A/*A genotype and 28% (7) patients were GSTA1 *A/*B heterozygous patients. There is no GSTA1 *B/*B homozygous patient. In all, 72% (18) and 20% (5) of patients were of GSTP1 *A/*A and GSTP1 *A/*G genotype. In all, 8% (2) were GSTP1 *G/*G genotype patients. All variants were in Hardy-Weinberg equilibrium. An overview of genotype and allele frequencies for all single-nucleotide polymorphisms is given in Table 2 .
Pharmacokinetics
The estimated clearance and daily AUC of once-daily i.v. BU were 4.02 ± 0.17 mL/min per kg and 3380.77 ± 147.036 μM/min, respectively. The estimated C max was 1.031 ± 0.0325 μg/mL. The estimated t 1/2 and V d were 3.618 ± 0.1932 h and 1.212 ± 0.0352 L/kg. The mean drug concentration and its s.d. at each time point are listed in Table 3 . The PK curves of once-daily i.v. BU are shown in Figure 1 .
The GSTA1 *A/*B genotype group showed significantly higher AUC(P o 0.0001) and C max (P = 0.0003) than the GSTA1 *A/*A genotype group. Lower clearance (P = 0.0007) and V d (P = 0.0331) were observed in the GSTA1 *A/*B genotype group compared with the GSTA1 *A/*A gentotype group (Figure 2 ). AUC increased with 38.26% in GSTA1 *A/*B and clearance increased with 27.86% in GSTA1 *A/*A genotype patients. C max increased 24.04% with GSTA1*A/*B gentotype patients. No difference was observed between two genotype groups in terms of t 1/2 .
AUC was significantly lower in GSTP1 *A/*A genotypes compared with*A/*G (P = 0.0129) and *G/*G genotypes (P = 0.0025).The BU clearance in GSTP1 *A/*A genotype was higher than *A/*G (P = 0.0325) and *G/*G genotypes (P = 0.0335). Lower t 1/2 was observed in GSTP1 *A/*A genotypes than in GSTP1 *A/*G (P = 0.0250) and GSTP1 *G/*G genotypes (P = 0.0198). In addition, the difference of C max was only observed between GSTP1 *A/*A genotype and GSTP1 *G/*G genotype (P = 0.0023). There was no difference between the two genotype groups in terms of V d (Figure 3 ). The details of the results are listed in Table 4 .
Response, relapse and survival At the end of follow-up, 15 patients were alive, including one patient who relapsed at 9 months after transplantation (survival after DLI). Three patients died because of disease relapse, two patients died from respiratory failure (one for bronchiolitis obliterans syndrome and one for invasive pulmonary aspergillosis) and one patient died of cerebral hemorrhage on day +10 after 
Abbreviations: GST = glutathione S-transferase; SNP = single-nucleotide polymorphism. Influence of GST gene polymorphisms on BU PK J Yin et al transplantation. A total of four deaths were related to grade IV acute GVHD. In all, 87.5% of the patients who failed to attain CR before transplant (n = 8) achieved CR after transplantation (n = 7). With a median follow-up of 32.7 months (range, 0.3-44.3 months), 2-year OS and EFS were 64 and 63.8% (Figure 4a ). The cumulative incidence of NRM for all patients at 100 days and 2 years was 12.2 and 21.2% (Figure 4b) , respectively, and the 2-year cumulative incidence of relapse for all patients was 18.3% (Figure 4c ). To further evaluate the clinical effects, subgroup analyses (by disease state, risk and genotype groups) were performed ( Figure 5 , Figure 6 ). The significant difference between the high-risk and standard-risk groups was observed in terms of the cumulative incidence of NRM (P = 0.048), and there were no significant differences in terms of OS, EFS, relapse and NRM (data not shown) between subgroups. The summary clinical outcomes are listed in Table 5 .
DISCUSSION
The advantages of i.v. BU as part of conditioning regimen before allo-HSCT have been proven by a series of studies. have indicated that once-daily i.v. BU had clinical efficacy similar to i.v. BU administered four times daily. The pharmacokinetic profiles and post transplant complications were similar for oncedaily i.v. BU and traditional four times daily i.v. BU. 4, 8, 10, [13] [14] [15] [16] [17] [18] In our study, a favorable prognosis was observed. All the patients achieved engraftment and 87.5% of the patients who failed to Abbreviations: AUC = area under the curve; GST = glutathione S-transferase; t 1/2 = half-life; V d = volume of distribution. Mean ± s.e.m.
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attain CR before transplant achieved CR after transplantation. With a median follow-up of 32.7 months, the 2-year OS and EFS were 64% and 63.8% for all the patients, respectively. In addition, the 2-year cumulative incidence of relapse was 18.3%. Similarly, research studies both in Asian and Caucasian populations reported such favorable outcomes. 14, 32 It is demonstrated that once-daily i.v. BU has comparable times to engraftment after transplantation and ideal therapeutic efficacy as traditional four times daily i.v. BU. 8, 14, 33, 34 In our study, the incidence rate of gastrointestinal toxicity (40%) was similar to the published data of another study (43.0%). 3 In addition, our patients had a much lower frequency (13.6%) and lower grades of oral mucositis (⩽ grade 2) compared with the previous study reported by Andersson 3 (44% had grade 2 and 26% had grade 3 mucositis). Besides, hepatotoxicity was low and no regimen-related HC after transplantation had occurred. Reversible increasing serum transaminase and bilirubin were recorded in six patients without GVHD. In addition, no VOD occurred even if five patients were either HBV carriers or with chronic HBV. Other severe side effects were also not observed in our study. All these findings showed that once-daily i.v. BU in Chinese patients had a good tolerance, favorable clinical outcomes and significantly low regimen-related toxicity. However, the cumulative incidence of NRM of our research at 100 days was 12.2%. It was higher than that reported by Russell 8 (5%) and Perkins 34 (6%). In addition, the cumulative incidence of NRM of our research at 2 years (21.2%) was still higher than 20.8% of a Korean clinical study reported by Ryu. 14 These differences can be explained by the fact that nearly half of the patients in those studies were patients with low risk, whereas the majority of our patients were with high risk. Low-risk patients could have a better treatment tolerance compared with high-risk patients. In general, once-daily i.v. BU neither increases the incidence of complications and mortality nor exacerbates the complications in Chinese patients. Our favorable clinical outcomes with once-daily i.v. Bu were consistent with previous research studies both in Caucasians and in Asian patients.
The PK analysis of our study indicated that once-daily i.v. BU in Chinese patients gave predictable linear kinetics, with more regularity and repeatability. Less variability was observed in different patients with different dosages in our study. This conclusion was consistent with previous studies. 4, 6, 8, 14, 36 In our study, the estimated clearance and daily AUC of once-daily i.v. BU were 4.02 ±0.17 mL/min per kg and 3380.77 ± 147.036 μM/min, respectively. The estimated C max was 1.031 ± 0.0325 μg/mL. The estimated t 1/2 and V d were 3.618 ± 0.1932 h and 1.212 ± 0.0352 L/kg. de Lima, 6 Russell, 8 14 There were 30 Korean patients with once-daily i.v. BU included. The estimated daily AUC was 6475.5 ± 1099.4 μM/min, and clearance was 1.91 ± 0.31 mL/min per kg, respectively. C max was 4.2176 μg/mL. V d and t 1/2 were 0.46 L/kg and 2.83 h. However, the estimated AUC and C max in Korean patients was much higher than that in both Chinese and Caucasian patients, and the clearance in Korean patients was lower than that in our patients and in Caucasian patients. According to these results, it is considered that oncedaily i.v. BU might have a faster metabolism in Chinese patients; this could be regarded as one of the reasonable explanations for the low incidence of hepatotoxicity and other regimen-related toxicities. Despite of the low C max and AUC in our study, the relapse rate did not increase significantly.
It is known that conjugation with glutathione is the primary route of metabolism of BU, catalyzed by isoenzymes of the GST protein superfamily. GSTA1 is the predominant GST isoenzyme involved. 23 single-nucleotide polymorphism in the genes encoding for the isoenzymes of GST could influence BU clearance. In addition, this effect may be dependent on ethnic groups. Therefore, we investigated the GSTA1 haplotype and the genetic variants for GSTP1 in our patients in order to search for the reasons for the decrease in AUC and C max and the increase in clearance compared with other studies. In our study, 72% of patients were GSTA1 *A/*A genotype and 28% patients were GSTA1 *A/*B heterozygous patients. There were no GSTA1 *B/*B homozygous patients. This result is exactly consistent with the studies reported by Kusuma et al. 37 and Kim et al. 38 These two studies included Japanese and Korean patients, respectively. Both studies detected no GSTA1 *B/*B homozygous patients and GSTA1 *A/*A homozygous patients made up the majority of the patients. However, according to the results of studies in Caucasian patients, 39, 40 all three genotypes were detected and the majority belonged to GSTA1 *A/*B heterozygous patients. Further analysis showed that the GSTA1 *A/*B genotype patients showed a significantly higher AUC and C max than GSTA1 *A/*A genotype group in our study. AUC increased by 38.26% and C max increased by 24.04% in GSTA1 *A/*B genotype patients. In addition, lower clearance was observed in the GSTA1 *A/*B genotype group. The clearance decreased by 27.86% in GSTA1 *A/*B genotype patients compared with GSTA1 *A/*A gentotype patients. Similar tendencies were also observed in both Korean and Caucasian adult patients. [37] [38] [39] However, in Caucasian patients, GSTA1 *B/*B genotype patients had the highest AUC value and the lowest clearance among three genotypes. What's more, it is reported that GSTP1 also contributed to BU metabolism. 36 In addition, GSTP1 has 18% of the activity of GSTA1 in BU metabolism. 23 In our study, 72 and 20% of patients were of GSTP1 *A/*A and GSTP1 *A/*G genotype. In all, 8% were GSTP1 *G/*G genotype patients. GSTP1 *A/*A homozygous patients accounted for the largest portion of the three genotypes. In Caucasian patients, it is reported that GSTP1 *A/*G heterozygous patients made up the majority of the patients. 39 Although no correlation between GSTP1 genotypes and PK was observed in Caucasian patients, 26, 39 significantly lower AUC and significantly higher clearance in GSTP1 *A/*A genotype were observed compared with*A/*G and *G/*G genotypes in our patients. However, the contribution of the GSTP1 enzymes to BU metabolism was less significant than GSTA1. Given the above, no GSTA1 *B/*B genotypes were found in Chinese patients, and Chinese patients might mainly consist of GSTA1 *A/*A genotype with lower AUC and higher clearance. On the contrary, GSTA1 *A/*B and GSTA1 *B/*B genotypes with significantly higher AUC and lower clearance than GSTA1 *A/*A genotype make up the majority of Caucasian patients. The differences in distribution frequency of GST gene polymorphism between Asian patients and Caucasian patients may be the most reasonable explanation for the different results between Chinese patients and Caucasian patients. Unfortunately, none of those studies independently evaluated the once-daily i.v. BU metabolism in their studies, which compromise a direct comparison with the results of our study. Kusuma et al. 37 included 12 Japanese patients with oral BU. Although influence of GST gene polymorphisms on once-daily i.v. BU PK was evaluated by Abbasi, 40 no actual values were shown. I.v. BU (0.8 mg/kg) was used four times daily in the study reported by ten Brink. 39 In the study reported by Kim et al., 38 patients were randomized to receive i.v. BU (3.2 mg/kg per day) either as a 4-time-daily regimen (0.8 mg/kg over 2 h, four times a day) or a once-daily regimen (3.2 mg/kg over 3 h, once a day). However, previous research studies have shown that there was no significant difference between once-daily i.v. BU and four times daily i.v. BU in terms of clearance.
14,32,36 Therefore, we compared our results with the data of the study reported by ten Brink 39 and the study reported by Kim. 38 It was shown that GSTA1 *A/*B genotype Caucasian patients had similar clearance to Chinese patients (3.0 vs 3.15 mL/min per kg). However, the clearance of GSTA1 *A/*A genotype Caucasian patients was lower than in Chinese patients (3.5 vs 4.4 mL/min per kg). GSTA1 *B/*B genotype Caucasian patients had the lowest values of clearance among three genotypes (2.5 mL/min per kg). Taking the different distribution frequencies of GST gene polymorphism into consideration between Chinese and Caucasian patients, these results support our previous speculation and explain the reasonable cause of lower clearance in Caucasian patients. However, in Korean patients, the values of clearance in both GSTA1 *A/*A and GSTA1 *A/*B genotype patients were lower than Chinese and Caucasian patients. The differences in the PK analysis between Chinese patients and Korean patients cannot be explained by the different distribution frequencies of GST gene polymorphism in different races. We speculated that possible explanations for the differences between Chinese and Korean patients may be summarized as follows. First, a variety of different diagnoses and different background therapies that could affect BU clearance were involved in both studies. Possibilities that these different backgrounds of patients may affect the BU metabolism cannot be ruled out. Future large-scale randomized trials need to be restricted to diagnosis and background therapies before transplantation. Besides, five patients were either HBV carriers or with chronic HBV in our study. Although no indices of liver damage were shown and no differences were observed in AUC and clearance between these patients and other patients, we cannot exclude the possibility of the influences caused by potential liver damage from pre-existing Hepatitis without knowing the details of liver function in Korean patients. Furthermore, we cannot rule out the possibility that regional differences in BU PK existed in Asian countries. In summary, our once-daily i.v. BU-based conditioning regimen for Chinese patients was very well tolerated and it could be achieved with acceptable toxicity and with favorable clinical outcomes, most likely because of dose assurance with predictable PK. Our results showed that associations between BU metabolism and GSTA1 and GSTP1 polymorphism in Chinese patients were observed. In addition, the differences of PK in BU among different ethnic groups existed because of the different distribution frequencies of GST gene polymorphism in Asian patients and Caucasian patients. The effect of GST gene polymorphism on BU PK did not seem to influence BU toxicity and clinical outcomes in our patients. As the number of our patients is limited and studies on GST polymorphisms on once-daily i.v. BU PK are less, further large-scale trials restricted to diagnosis and background therapies before transplantation are required. Abbreviations: GST = glutathione S-transferase; NRM = non-relapse mortality.
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